{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-085044","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.992181+00:00","generated_at":"2026-05-31T18:37:15.231248+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent doses first patient in Phase 1 trial of HER2-selective inhibitor NVL-330 for NSCLC","bullets":["Initiated HEROEX-1 Phase 1a/1b trial evaluating NVL-330 in pre-treated patients with HER2-altered NSCLC.","First patient dosed on July 22, 2024; trial will assess safety, tolerability, PK, and preliminary anti-tumor activity.","Trial objectives include determination of recommended Phase 2 dose (RP2D) for NVL-330."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-085044","json":"https://secwatch.observer/filing/0000950170-24-085044.json","markdown":"https://secwatch.observer/filing/0000950170-24-085044.md","text":"https://secwatch.observer/filing/0000950170-24-085044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/0000950170-24-085044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/nuvl-20240722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:37:15.231248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}